Dose reduction index of cytarabine or other drugs when combined with TAK-981 in AML cell lines
| Cell line . | Combination drug . | Dose reduction index at fraction affected (Fa) = 0.9 . |
|---|---|---|
| U937 | Cytarabine | 12.03 |
| THP-1 | Cytarabine | 1.25 |
| KG-1 | Cytarabine | 2.61 |
| MOLM-14 | Cytarabine | 2.94 |
| MOLM-14 | Azacitidine | 4.87 |
| MOLM-14 | Quizartinib | 8.64 |
| MOLM-14 | Venetoclax | 4.98 |
| Cell line . | Combination drug . | Dose reduction index at fraction affected (Fa) = 0.9 . |
|---|---|---|
| U937 | Cytarabine | 12.03 |
| THP-1 | Cytarabine | 1.25 |
| KG-1 | Cytarabine | 2.61 |
| MOLM-14 | Cytarabine | 2.94 |
| MOLM-14 | Azacitidine | 4.87 |
| MOLM-14 | Quizartinib | 8.64 |
| MOLM-14 | Venetoclax | 4.98 |
Fa = 0.9 refers to the point where the inhibition effect is 90%, that is, when 90% of the cells are dead. The number 0.9 was chosen, because for cancer therapies, high effect levels are thought to be more therapeutically relevant than low effect levels.32